FPT Achieves 2024 EcoVadis Platinum Rating for Sustainability Through Its French Subsidiary
12.12.2024 08:24:00 CET | Business Wire | Press release
Global technology corporation FPT recently achieved the EcoVadis Platinum rating through its French subsidiary. This is the highest distinction in the survey conducted by EcoVadis, an international organization that evaluates corporate sustainability activities. The recognition places FPT in the top 1% of companies evaluated worldwide for their commitment to sustainable business practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211227891/en/
(Graphic: Business Wire)
The EcoVadis rating is a comprehensive assessment of a company’s environmental, social, and governance (ESG) practices. It includes a global network of over 130,000 companies of various sizes across 220+ industries and 180+ countries. Sustainability performance is assessed across 21 criteria in four themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
FPT attained an overall score of 88/100, with impressive ratings of 90/100 for both Labor & Human Rights and Ethics, and 80/100 for the Environment category. This achievement reflects the company’s commitment to all dimensions of environmental policies, efficient corporate governance protocols, robust employee professional development initiatives, and dedication to reducing carbon emissions.
Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software, FPT Corporation, said: “FPT’s recognition by EcoVadis comes as part of our broader sustainability strategy, which includes embracing technologies, cultivating future-ready talents and driving new values that will last generations. Moving forward, we will continue to prioritize sustainability across all levels of our operations, with ongoing initiatives and investments to integrate sustainable practices into our solutions and services, as well as the work we deliver to our global customers.”
In 2023, FPT received a Silver rating from EcoVadis, further demonstrating its dedication to sustainable and ethical practices. In 2024, the company achieved ISO 45001 certification, the international standard for occupational health and safety, across its twelve campuses and offices in Vietnam, Germany, and France. Additionally, FPT won the Job Creation Award at ESGBusiness Awards 2024 and joined the Pledge 1% movement, reinforcing its dedication to corporate social responsibility and community engagement.
Since entering France in 2008, FPT has solidified its market position and demonstrated its expertise by collaborating with global leaders such as Airbus, La Poste, Air Liquide, Quadient, etc. In 2023, the French subsidiary entered France's top 100 ICT Companies. That same year, the company further strengthened its capabilities by acquiring an 80% stake in French IT consulting firm AOSIS, enhancing its expertise in SAP, Data, Cloud, and smart solutions tailored for the aerospace, aviation, and transportation industries. Looking ahead, FPT aims to be among the Top 50 IT companies in France, targeting to expand its local workforce to over 500 experts and its presence in France and neighbouring Francophone countries.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information about global IT services, please visit https://fptsoftware.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211227891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom